Owing to differences in targeted anticoagulant intensities in japan, japanese patients were not enrolled into the global studies. Einsteinpulmonary embolism pe study american college of. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In contrast, for the amplify trial, this percentage was. Rivaroxaban equals standard therapy, halves major bleeding. Rivaroxaban for treating pulmonary embolism and preventing. Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism vte in adult patients. The simplified pe severity index spesi is one of several validated prognostic tools for acute pulmonary embolism pe.
In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily thereafter was shown to be an effective and safe. Original clinical investigation open access oral rivaroxaban. The primary efficacy outcome occurred in 17 of 1107 patients 1. Treatment of deep vein thrombosis dvt, pulmonary embolism pe, and reduction in the risk of recurrence of dvt and of pe. Dec 16, 20 the einstein dvt and einstein pe studies evaluated rivaroxaban for the treatment of vte. In the einstein pe study, most participants had unprovoked pe rivaroxaban arm 65%, enoxaparin plus warfarin or acenocoumarol arm 64%, 17% had pe due to recent surgery or trauma and 16% had pe due to immobilisation. Apixaban and rivaroxaban in patients with acute venous. This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism pe with or without symptomatic deepvein thrombosis dvt einstein pe. Pdf rivaroxaban for the treatment of pulmonary embolism. Published in, einsteinpe randomized 4, patients with acute pe to rivaroxaban or standard therapy with enoxaparin and a vka.
In the einsteindvt and einsteinpe trials, in over 8,000 patients. A fixeddose regimen of rivaroxaban, an oral factor xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deepvein thrombosis, without the need for. The einstein pe study was a randomized, openlabel trial of the efficacy and safety of rivaroxaban as compared with standard therapy consisting of enoxaparin and a vitamin k antagonist in. Randomized, openlabel phase iii noninferiority study active treatment. Oral rivaroxaban versus standard therapy for the treatment of. In this large, international, phase iii clinical program in more than 8000 patients with acute symptomatic dvt andor pe, monotherapy with rivaroxaban was shown to be as effective as dualdrug therapy with enoxaparin overlapping with and followed by vka. Einstein dvt and einstein pe were randomized, openlabel studies that compared the efficacy and safety of rivaroxaban with standard therapy, consisting of enoxaparin and adjusteddose vka, in patients with acute, symptomatic dvt andor pe. Direct oral anticoagulants compared with vitamin k. It is administered at a fixed oral dose and does not require routine coagulation monitoring. Each study was eventdriven and required a number of events to provide 90% power using a margin of 2. In summary, the einsteinpe study demonstrated that rivaroxaban, an oral factor xa inhibitor, can be administered without laboratory monitoring in the prevention of recurrent thromboembolism following an acute pe. Oral direct factor xa inhibitor rivaroxaban in patients. Rivaroxaban xarelto for treatment of deep vein thrombosis. Dec 16, 20 the worldwide einstein dvt and einstein pe studies randomized 8282 patients with acute symptomatic deepvein thrombosis dvt andor pulmonary embolism pe and, for the first time in trials in this setting, included patients in china.
Oral direct factor xa inhibitor rivaroxaban in patients with. Oral rivaroxaban for symptomatic venous thromboembolism. Rivaroxaban or aspirin for extended treatment of venous. Among patients in the einstein choice trial who had completed a 6 to 12month course of anticoagulation for vte, extending anticoagulation with either prophylaxis 10 mg or treatment 20 mg doses of rivaroxaban for 1 year is superior to aspirin in reducing recurrent vte events. In the einsteinpe study, most participants had unprovoked pe rivaroxaban arm 65%, enoxaparin plus warfarin or acenocoumarol arm 64%, 17% had pe due to recent surgery or trauma and 16% had pe due to immobilisation. Sep 18, 2014 six studies were included, evaluating the direct thrombin inhibitor dabigatran recover and recover ii studies 1,2, and the factor xa inhibitors rivaroxaban einstein dvt and einstein pe studies 5,6, apixaban amplify study 4, and edoxaban hokusaivte study 3. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily thereafter. Einsteinpe investigators, buller hr, prins mh, lensin aw, decousus h, jacobson bf, minar e, chlumsky j, verhamme p, wells p, agnelli g. Rivaroxaban for the treatment of symptomatic deepvein thrombosis and pulmonary embolism in chinese patients. Oral rivaroxaban for the treatment of symptomatic pulmonary. Oral, direct factor xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism. Cosimo patients with active cancer changing to rivaroxaban. Patients were eligible if they were of legal age and had objectively confirmed acute. Vka day 1 day 5 11 at least 3 months current standard of care recover dabigatran hokusaivte edoxaban einsteindvtpe rivaroxaban amplify apixaban lmwh sc dabigatran bidedoxaban od rivaroxaban 15 mg bid 3 weeks, then 20 od apixaban 10 mg bid 1 week, then 5 bid day 1 day 5 11 at least 3 months.
Oral rivaroxaban for the treatment of symptomatic venous thromboembolism einstein. Oct 12, 2017 the simplified pe severity index spesi is one of several validated prognostic tools for acute pulmonary embolism pe. Sep 05, 2019 einsteinpe investigators, buller hr, prins mh, lensin aw. Rivaroxaban for the treatment of venous thromboembolism in. Patientreported treatment satisfaction with oral rivaroxaban. Patients in this substudy were representative of the overall global einstein pe population with, for example, a mean age of approximately 58 years in both groups, with male.
Phase 2 dosefinding studies and studies evaluating extended anticoagulant. Clinical data were collected from the medical history of the patients and recorded in a specific database. The european society of cardiology recommended the use of the spesi to riskstratify patients with acute pe into low risk spesi0 and nonlow risk spesi. The clinical profile, evolution and complications of treatment with rivaroxaban in a cohort of patients presenting with venous thromboembolism vte were analyzed in an observational, noninterventional and prospective study a total of 111 patients were included in the study. Of the 4,833 patients randomised in the einstein pe study, 2,397 participated in the patient satisfaction substudy, of whom 1,200 patients received rivaroxaban and 1,197 patients received enoxaparinvka. Oral rivaroxaban alone for the treatment of symptomatic. A prespecified pooled analysis of the einsteindvt and einsteinpe studies compared the efficacy and safety of rivaroxaban 15 mg. Rivaroxaban is an oral, direct factor xa inhibitor, approved for the treatment of pulmonary embolism pe and deep vein thrombosis dvt and the secondary prevention of recurrent pe and dvt as a fixeddose, monotherapy regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. In summary, the einstein pe study demonstrated that rivaroxaban, an oral factor xa inhibitor, can be administered without laboratory monitoring in the prevention of recurrent thromboembolism following an acute pe. Listing a study does not mean it has been evaluated by the u. Aug 21, 2012 have the einsteinpe investigators reported what is probably the next important advance in the treatment of pe. Weighing the options for anticoagulation in obesity. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Treatment of acute pe with rivaroxaban in daily care n 72 showed that patients in this analysis were older than the overall einstein pe population 67. Jan 17, 2015 the global einstein dvt and pe studies compared rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily with enoxaparinvitamin k antagonist therapy and demonstrated noninferiority for efficacy and superiority for major bleeding. The new oral factor xa inhibitor rivaroxaban proved equivalent to standard care of lmwh plus vitamink antagonist for the treatment of acute pulmonary embolism in the einstein pe study reported today. Published in, einstein pe randomized 4, patients with acute pe to rivaroxaban or standard therapy with enoxaparin and a vka. There are limited clinical data in patients with crcl 15 to mar 27, 2012 einstein ext evaluated 1,197 patients who had previously completed six to 12 months of treatment with a vka for an acute episode of vte or have participated in the phase 3 einstein dvt or einstein pe trials, in which they were treated with either rivaroxaban or a vka, for the same time duration. Oral direct factor xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism the einstein pe study. Rivaroxaban n2412 enoxaparinvka n2405 number of patients at risk rivaroxaban 2412 2281 2248 2156 2091 2063 17 761 735 700 669 659 350 enoxaparinvka 2405 2270 2224 2116 2063 2036 1176 746 719 680 658 642 278 einstein pe. Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous. Obese patients in rivaroxaban studies study intervention bmi number % 90kg rocketaf atrial fibrillation rivaroxaban 20mg daily warfarin 28. Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults. The study of rivaroxaban for acute dvt included 3449 patients. Final appraisal determination rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism issue date. The results show that replacing the effective, but cumbersome, combination of injectable and oral agents at initiation of anticoagulation with a single oral anticoagulantrivaroxaban, which does not need routine monitoringproduced efficacy and safety outcomes that were similar. Based on the results of einstein dvt and einstein pe, the approved.
A fixeddose regimen of rivaroxaban, an oral factor xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deepvein thrombosis, without the need for laboratory monitoring. Sep 20, 20 the einstein dvt and einstein pe studies were each designed to test the hypothesis that rivaroxaban would be noninferior to standardtherapy. Rivaroxaban for the treatment of venous thromboembolism in r. Pdf rivaroxaban and the einstein clinical trial programme. Einsteinpe investigators, buller hr, prins mh, lensin aw.
Jun 30, 2019 einstein pe rivaroxaban pdf oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The approval of rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism and the extended secondary prevention of recurrent vte is based on the results of the einstein dvt and einstein pe trials, and the einstein. Rivaroxaban for the treatment of symptomatic deepvein. This analysis evaluates the results of these studies in this subgroup of patients. Sep 20, 20 two studies, einstein dvt and einstein pe, compared a singledrug approach using the oral, direct factor xa inhibitor rivaroxaban with standardtherapy consisting of enoxaparin overlapping with and followed by a vka for the treatment of dvt andor pe 8, 9. A fixeddose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and longterm treatment of pulmonary embolism and had a potentially improved benefitrisk profile. Noacs in vte drug selection according to patients risk. Einstein pe investigators, buller hr, prins mh, lensin aw.
Einstein pe rivaroxaban pdf oral rivaroxaban for the treatment of symptomatic pulmonary embolism. A prespecified pooled analysis of the einstein dvt and einstein pe studies compared the efficacy and safety of rivaroxaban 15 mg twicedaily for 21 days, followed by 20 mg oncedaily with standardtherapy enoxaparin 1. Rivaroxaban and the einstein clinical trial programme. Funded by bayer healthcare and janssen pharmaceuticals. Patients were treated for 3, 6, or 12 months and followed for. Study and the study committees are listed in the supplementary. The approval of rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism and the extended secondary prevention of recurrent vte is based on the results of the einstein dvt and einstein pe trials, and the einstein ext and einstein choice trials. Reduceddosed rivaroxaban in the longterm prevention of. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism einstein pe.
A total of 439 chinese patients who had acute symptomatic dvt n211, or pe. A subgroup analysis of pooled results from einstein dvt and einstein pe demonstrated that the rate of recurrent vte was similarly reduced in patients treated with rivaroxaban or enoxaparinvka therapy, and that the number of major bleeding events was reduced with rivaroxaban therapy in patients with or without active cancer. Although effective, treatment with warfarin requires frequent blood tests and is thus burdensome for patients. A potentially fatal condition caused by a blood clot blocking a vessel in the lung. Oral rivaroxaban versus standard therapy for the treatment. Rivaroxaban and usual care had similar rates of recurrent vte. A prespecified pooled analysis of the einsteindvt and einstein pe studies compared the efficacy and safety of rivaroxaban 15. The goal of the trial was to evaluate treatment of the oral direct factor xa inhibitor, rivaroxaban, compared with standard therapy among patients. Mar 24, 2019 einsteinpe investigators, buller hr, prins mh, lensin aw. In patients with crcl rivaroxaban exposure and pharmacodynamic effects are increased compared to patients with normal renal function. The einsteindvt and einsteinpe studies were each designed to test the hypothesis that rivaroxaban would be noninferior to standardtherapy.
1263 1135 515 522 305 1654 161 1612 233 1187 514 413 652 142 336 1190 1200 1280 1390 1450 1565 475 946 948 625 190 633 287 162 968 1480 1088 1437 944